ANDREA
MAYADO COLINO
Investigadora no período 2012-2013
Andrés Celestino
García Montero
Profesor Asociado
Publicacións nas que colabora con Andrés Celestino García Montero (26)
2024
-
Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723
-
T-cell immune profile in blood of systemic mastocytosis: Association with disease features
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 7, pp. 1921-1937
2023
-
Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 5, pp. 1536-1547
-
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1347-1359
-
Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality
The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919
2022
-
Altered innate immune profile in blood of systemic mastocytosis patients
Clinical and Translational Allergy, Vol. 12, Núm. 6
-
Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis
Blood, Vol. 139, Núm. 4, pp. 572-583
2021
-
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
The Lancet Haematology, Vol. 8, Núm. 3, pp. e194-e204
2019
-
Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis
International Journal of Molecular Sciences, Vol. 20, Núm. 3
-
Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis
Blood, Vol. 134, Núm. 5, pp. 456-468
2018
-
Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 6, pp. 1294-1304
-
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
Blood Advances, Vol. 2, Núm. 21, pp. 2814-2828
2017
-
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
Oncotarget, Vol. 8, Núm. 40, pp. 68950-68963
2016
-
Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis
Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 1, pp. 168-178.e1
-
Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia
Leukemia
-
Diagnosis and classification of mastocytosis in non-specialized versus reference centres: A Spanish Network on Mastocytosis (REMA) study on 122 patients
British Journal of Haematology, Vol. 172, Núm. 1, pp. 56-63
-
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression
Leukemia, Vol. 30, Núm. 1, pp. 124-130
-
KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression
Blood, Vol. 127, Núm. 6, pp. 761-768
2015
-
Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: Diagnostic implications
Modern Pathology, Vol. 28, Núm. 8, pp. 1138-1149
-
Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow
Stem Cell Research and Therapy, Vol. 6, Núm. 1